Embecta Discontinues FDA-Cleared Insulin Patch Pump Amid Strategic Restructuring

Embecta's decision to discontinue its insulin patch pump comes shortly after the product received FDA clearance, as part of the company's strategic restructuring[1]. Despite the technical achievement, Embecta opted not to pursue a full market launch because the open-loop system requires manual adjustments, which falls short of market demands for more advanced closed-loop systems[2]. The company determined that developing a competitive closed-loop pump would necessitate significant time and investment, resources better spent on paying down its $1.6 billion debt and focusing on core products[1]. Attempts to find commercial opportunities for the open-loop pump proved fruitless, leading to its discontinuation, which is anticipated to save $60 million to $65 million in fiscal 2025[1][2].